|
Main
|
|
Note: This record shows only the 20 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
17 October 2012 |
|
Main ID: |
NCT01361412 |
|
Date of registration:
|
24/05/2011 |
|
Primary sponsor: |
|
|
Public title:
|
Identification of Potential Biomarkers of Response to Peptide Immunotherapy for Ragweed Allergy
|
|
Scientific title:
|
An Optional Research Study to Identify Potential Biomarkers of Response to Peptide Immunotherapy for Ragweed Allergy in Subjects Already Enrolled in Clinical Study TR002 |
|
Date of first enrolment:
|
March 2011 |
|
Target sample size:
|
20 |
|
Recruitment status: |
Completed |
|
URL:
|
http://clinicaltrials.gov/show/NCT01361412 |
|
Study type:
|
Interventional |
|
Study design:
|
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)
|
|
|
Countries of recruitment
|
|
Canada
| | | | | | | |
|
Contacts
|
|
Name:
|
Deepen Patel, MD, CCFP |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
Cetero Research, San Antonio |
| | |
|
Key inclusion & exclusion criteria
|
Inclusion Criteria:
- Enrolled in study TR002 but have not yet commenced dosing
Exclusion Criteria:
- None; no criteria additional to TR002 exclusion criteria are applicable to this study
Age minimum:
18 Years
Age maximum:
65 Years
Gender:
Both
|
|
Health Condition(s) or Problem(s) studied
|
|
Ragweed Allergy
|
|
Intervention(s)
|
|
Biological: Placebo
|
|
Biological: ToleroMune Ragweed
|
|
Primary Outcome(s)
|
|
Identification of potential plasma biomarkers of response to peptide immunotherapy
[Time Frame: 6 months after start of dosing]
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|